Harnessing the power of the human microbiome to prevent and treat disease.
We are leveraging the untapped potential of the human microbiome to develop novel medicinal products that restore health and prevent disease, with a specific focus on drug-resistant bacterial infections.
EnteroBiotix is developing novel microbiome modulating drugs designed to restore health and prevent disease through diverse and viable donor-derived microbial communities. These drugs build on the science and evidence base underpinning human microbiota transfer, which studies have shown to be a remarkably effective therapeutic intervention for a number of challenging diseases and infections.
We have established deep operational experience, an international hospital and clinical network, integrated microbial collection and MHRA-licensed operational capabilities. Our whole community microbiome product has been successfully distributed for use in hospitals in the United Kingdom and European Union with positive outcomes reported in patients. We have manufactured over 200 MP batches of whole community products.
Our integrated collection and manufacturing capabilities support interventional clinical trials under an MHRA MIA(IMP) license as well as named-patient treatment under an MHRA ‘Specials’ license. All donated material is obtained from rigorously screened and healthy donors that meet up-to-date inclusion criteria published in consensus and regulatory guidelines. EnteroBiotix has successfully distributed products to patients in the UK and the EU.